Reading ANAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANAB free→Reading ANAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANAB free→QuarterlyIQ Insights · ANAB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure. AnaptysBio, Inc. (the “Company”) has filed Form 8937 with the IRS and will also post Form 8937 information under the “Investors” section of its website at www.anaptysbio.com. The Form 8937 provides information about the dividend received by stockholders resulting from the separation and spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks”) from the Company. The Form 8937 also provides guidance on how the dividend is treated by the Company’s stockholders and…
Results of Operations and Financial Condition. On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On May 11, 2026, AnaptysBio, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Christopher M. Murphy as Chief Financial Officer, effective as of May 11, 2026. Mr. Murphy previously served as Chief Financial Officer for Third Harmonic Bio, Inc. from January 2024 to December 2025…
Other Events. On April 20, 2026, the Company issued a press release announcing the completion of the Spin-Off. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this
Entry into a Material Definitive Agreement. In connection with the Spin-Off, the Company and First Tracks Biotherapeutics entered into a separation and distribution agreement (the “Separation and Distribution Agreement”) and a transition services agreement (the “Transition Services Agreement”) to effect the Spin-Off. Separation and Distribution Agreement We entered into a Separation and Distribution Agreement with First Tracks Biotherapeutics before the Spin-Off that sets forth our agreements…
Completion of Acquisition or Disposition of Assets. On April 20, 2026, the Spin-Off was completed in accordance with the Separation and Distribution Agreement. The description of the Spin-Off included under the Explanatory Note of this Current Report on Form 8-K is incorporated into this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Board Departures In connection with the Spin-Off, each of Dennis Fenton, Rita Jain and Magda Marquet resigned from the board of directors of the Company, effective as of April 20, 2026, and J. Anthony Ware resigned from the board of directors of the Company, effective as of April 23, 2026. Executive Officer Transitions In connection with the Spin-O…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On March 26, 2026, the Board appointed Susannah Gray as a Class I director, a member of the Nominating and Corporate Governance Committee and a member of the Research and Development Committee, effective immediately. In connection with her appointment as a non-employee director of the Board, Ms. Gray will receive an initial…
by reference. The information furnished in Item 7.01, including Exhibits 99.1, 99.2 and 99.3, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in s…
Termination of a Material Definitive Agreement. As previously disclosed, on November 5, 2024, the Company entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (the “Agent”), pursuant to which the Company could issue and sell, from time to time, shares of its common stock, par value $0.001 per share (the “Common Shares”), up to an aggregate offering price equal to the Maximum Amount (the “ATM Program”). The Company has issued a termination letter to the Agent to…
Entry into a Material Definitive Agreement. On March 26, 2026, First Tracks Biotherapeutics and EcoR1 Capital Fund Qualified, L.P. (the “Selling Stockholder”) entered into a purchase agreement (the “Purchase Agreement”) with certain third party investors (collectively, the “Investors”), pursuant to which SpinCo agreed to issue and sell an aggregate 5,791,478 shares of SpinCo’s common stock, par value $0.001 per share (the “Common Stock”) (collectively, the “Primary Shares”), and the Selling S…
Results of Operations and Financial Condition. On March 3, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Results of Operations and Financial Condition. On January 11, 2026, AnaptysBio, Inc. (“AnaptysBio”) expects to disclose certain preliminary, unaudited financial information in connection with presentations (the “Presentation”) to be held at the 2026 J.P. Morgan Healthcare Conference, including that AnaptysBio expects to report that it had cash and cash equivalents and investments of approximately $310 million as of December 31, 2025. Anaptys’ audited financial statements for the fiscal year e…
Regulation FD Disclosure. On November 20, 2025, as previously announced, AnaptysBio, Inc. (“ AnaptysBio ”) filed a Verified Complaint (the “ AnaptysBio Complaint ”) in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (“ Tesaro ”) has materially breached the parties’ Collaboration and Exclusive License Agreement (“ Collaboration Agreement ”) and that GlaxoSmithKline (“ GSK ” ) , Tesaro’s corporate parent, has tortiously interfered with the Collaboration Agreement. Anap…
Other Events. On November 20, 2025, AnaptysBio, Inc. ( AnaptysBio ) filed a Verified Complaint (the “ Complaint ”) in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. has materially breached the parties’ Collaboration and Exclusive License Agreement (“ Collaboration Agreement ”) and that GlaxoSmithKline (“ GSK ” ) , Tesaro’s corporate parent, has tortiously interfered with the Collaboration Agreement. AnaptysBio has requested that the court declare that AnaptysBio is…
Other Events. On November 21, 2025, AnaptysBio, Inc. (“Anaptys”) issued a press release (the “Press Release”) announcing that its Board of Directors authorized an amendment to its Stock Repurchase Plan previously approved in March 2025, under which the Company may repurchase up to an additional $100.0 million of the Company’s outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remains available under the Stock Repurchase Plan as of Nove…
Results of Operations and Financial Condition. On November 4, 2025, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…
Results of Operations and Financial Condition. On August 6, 2025, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and six months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…
Results of Operations and Financial Condition. On May 5, 2025, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or o…
Other Events. On March 24, 2025, AnaptysBio, Inc. (“AnaptysBio”) issued a press release (the “Press Release”) announcing that its Board of Directors authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On February 27, 2025, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934…
Other Events. On February 12, 2025, AnaptysBio announced the Top-Line Data from the global 424-patient Phase 2b RENOIR trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis (RA). The Phase 2b RENOIR trial is evaluating the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of rosnilimab in patients with moderate-to-severe RA on background conventional disease-modifying antirheumatic drugs (cDMARDs) (e.g., m…
Entry into a Material Definitive Agreement. On January 31, 2025, AnaptysBio, Inc. ( “ Anaptys ” ) entered into an Exclusive License Agreement (the “ License Agreement ” ) with Vanda Pharmaceuticals Inc. ( “ Vanda ” ) pursuant to which Anaptys granted to Vanda an exclusive, global license for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'fair' to 'full'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.